NO814337L - Fremgangsmaate og preparat til behandling av sykdom, saerlig leddbetennelse - Google Patents
Fremgangsmaate og preparat til behandling av sykdom, saerlig leddbetennelseInfo
- Publication number
- NO814337L NO814337L NO814337A NO814337A NO814337L NO 814337 L NO814337 L NO 814337L NO 814337 A NO814337 A NO 814337A NO 814337 A NO814337 A NO 814337A NO 814337 L NO814337 L NO 814337L
- Authority
- NO
- Norway
- Prior art keywords
- accordance
- preparation
- cobalt
- approx
- administered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 18
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 9
- 229960002104 cyanocobalamin Drugs 0.000 claims description 9
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 9
- 239000011666 cyanocobalamin Substances 0.000 claims description 9
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims description 8
- 239000010941 cobalt Substances 0.000 claims description 7
- 229910017052 cobalt Inorganic materials 0.000 claims description 7
- 150000001869 cobalt compounds Chemical class 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 208000024335 physical disease Diseases 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 3
- 150000002497 iodine compounds Chemical class 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 description 9
- 239000000126 substance Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ19588180 | 1980-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO814337L true NO814337L (no) | 1982-06-21 |
Family
ID=19919447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO814337A NO814337L (no) | 1980-12-19 | 1981-12-18 | Fremgangsmaate og preparat til behandling av sykdom, saerlig leddbetennelse |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4387093A (da) |
| EP (1) | EP0055118A1 (da) |
| JP (1) | JPS57131721A (da) |
| AU (1) | AU565090B2 (da) |
| DK (1) | DK564881A (da) |
| GB (1) | GB2089660A (da) |
| NO (1) | NO814337L (da) |
| NZ (1) | NZ195881A (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT376879B (de) * | 1982-10-27 | 1985-01-10 | Gerot Pharmazeutika | Verfahren zur herstellung einer injektionsloesung |
| EP0125252A1 (de) * | 1982-11-16 | 1984-11-21 | MOTSCHAN, Georges | Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine |
| US4663165A (en) * | 1985-04-12 | 1987-05-05 | Elena Avram | Method for counteracting the adverse effects of sodium chloride |
| US4628052A (en) * | 1985-05-28 | 1986-12-09 | Peat Raymond F | Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities |
| US5061477A (en) * | 1989-04-11 | 1991-10-29 | The Rockefeller University | Use of cobalt to enhance urinary copper excretion |
| DE4319629A1 (de) * | 1993-06-15 | 1994-12-22 | Karsten Klingelhoeller | Verwendung von Corrinoiden zur topischen Anwendung bei Hauterkrankungen |
| WO1995031204A1 (en) * | 1994-05-17 | 1995-11-23 | Research Corporation Technologies, Inc. | Cobalamins as nitric oxide sequestrants |
| US5958462A (en) * | 1997-05-23 | 1999-09-28 | Mclean; Linsey | Therapeutic bath salts and method of use |
| US6146639A (en) * | 1999-07-26 | 2000-11-14 | Merich Nick | Arthritis, muscle pain, and dry skin remedy |
| US20030235629A1 (en) * | 1999-11-06 | 2003-12-25 | Janmarie Hornack | Dietary supplement containing alkaline electrolyte buffers |
| DE10053155A1 (de) * | 2000-10-26 | 2002-05-08 | Erika Jungkeit | Verwendung eines Multivitaminpräparats zur Behandlung der Schuppenflechte |
| DE10130846A1 (de) * | 2001-06-28 | 2003-01-16 | Regeneratio Pharma Ag | Verwendung von Corrinoiden zur Anwendung bei Hauterkrankungen |
| US7611732B2 (en) * | 2004-07-26 | 2009-11-03 | Michael Bentley | Nutritional supplement for osteoarthritis |
| US20130064903A1 (en) * | 2011-09-08 | 2013-03-14 | Lucille Townsend-Byrd | Rheumatiod arthritis cure |
| CN105326856B (zh) * | 2015-10-23 | 2018-03-13 | 四川农业大学 | 一种动物抗贫血微囊的制备方法及其动物营养用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3876765A (en) * | 1968-05-03 | 1975-04-08 | Choay Sa | Pharmaceutical composition containing vitamin b' 12', process of making the same and method of treatment therewith |
| US4007266A (en) * | 1968-05-03 | 1977-02-08 | Choay S.A. | Pharmaceutical composition containing vitamin B12, process of making the same and method of treatment |
| US4085206A (en) * | 1973-05-31 | 1978-04-18 | Ceskoslovenska Akademia Ved | Composition for treatment of infectious diseases in animals |
| US4009263A (en) * | 1974-02-15 | 1977-02-22 | Shafer Laverne | Energized cobalt-containing animal feed |
| FR2429021A1 (fr) | 1978-06-20 | 1980-01-18 | Beres Jozsef | Composition pharmaceutique utile dans le traitement de diverses maladies par action sur le systeme reticuloendothelial et application de cette composition au traitement de tumeurs malignes en therapeutique humaine |
-
1981
- 1981-12-14 NZ NZ195881A patent/NZ195881A/en unknown
- 1981-12-17 AU AU78607/81A patent/AU565090B2/en not_active Ceased
- 1981-12-18 GB GB8138306A patent/GB2089660A/en active Pending
- 1981-12-18 US US06/332,342 patent/US4387093A/en not_active Expired - Lifetime
- 1981-12-18 NO NO814337A patent/NO814337L/no unknown
- 1981-12-18 DK DK564881A patent/DK564881A/da not_active Application Discontinuation
- 1981-12-19 JP JP56206026A patent/JPS57131721A/ja active Pending
- 1981-12-21 EP EP81306007A patent/EP0055118A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2089660A (en) | 1982-06-30 |
| AU7860781A (en) | 1982-06-24 |
| EP0055118A1 (en) | 1982-06-30 |
| DK564881A (da) | 1982-06-20 |
| AU565090B2 (en) | 1987-09-03 |
| JPS57131721A (en) | 1982-08-14 |
| NZ195881A (en) | 1984-08-24 |
| US4387093A (en) | 1983-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508975A5 (da) | ||
| US4405596A (en) | Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level | |
| ES2239799T3 (es) | Uso de tetrahidrolipstatina en el tratamiento de la diabetes tipo ii. | |
| US5397574A (en) | Controlled release potassium dosage form | |
| US5393531A (en) | Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation | |
| US4387093A (en) | Arthritis treatment | |
| JPS62501845A (ja) | 制御放出塩化カリウム | |
| EP0015334B1 (en) | Carminative preparations containing peppermint oil or its active components | |
| EP0150792B1 (de) | Arzneimittel und die Verwendung schwerlöslicher Calcium- und/oder Magnesiumverbindungen zur Herstellung eines Arzneimittels | |
| AU4478096A (en) | Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins | |
| JPS5942649B2 (ja) | 重症筋無力症治療剤 | |
| US3917832A (en) | Compositions comprising d-thyroxine and d-triiodothyronine | |
| RU2176893C2 (ru) | БИОЛОГИЧЕСКИ АКТИВНАЯ ДОБАВКА К ПИЩЕ "ДНКаВИТ" | |
| US5026706A (en) | Method for treating dysuria using naftopidil | |
| US4565830A (en) | Method of ameliorating the subjective symptoms and objective signs in congestive heart failure | |
| AU651824B2 (en) | Pharmaceutical composition | |
| US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
| EP0372676A1 (en) | Therapeutic preparation and method | |
| US3133860A (en) | Method of treating alimentary canal ulcers with sagebrush oil | |
| US3565560A (en) | Pharmaceutical preparation containing hydrofuramide and method of using it | |
| US3963834A (en) | Pharmaceutical compositions for the treatment of hydropic conditions | |
| JPS5938206B2 (ja) | 補酵素ｑを主成分とする気管支喘息治療剤 | |
| JPS5938204B2 (ja) | 再生不良性貧血治療剤 | |
| WO2003000299A1 (en) | Laxative preparation | |
| JP2002542198A (ja) | 抗躁薬および気分変動の安定薬としてのルビジウムおよび特に塩化ルビジウムの使用 |